LG Life Sciences, Ltd – Product Pipeline Review – H2 2011

Published : November 2011
No. of Pages : 83

Price:

Summary

Global Market Direct’s pharmaceuticals report, “LG Life Sciences, Ltd - Product Pipeline Review - H2 2011” provides data on the LG Life Sciences, Ltd’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, LG Life Sciences, Ltd’s corporate website, SEC filings, investor presentations and featured press releases, both from LG Life Sciences, Ltd and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- LG Life Sciences, Ltd - Brief LG Life Sciences, Ltd overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of LG Life Sciences, Ltd human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of LG Life Sciences, Ltd with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the LG Life Sciences, Ltd’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate LG Life Sciences, Ltd’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of LG Life Sciences, Ltd in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the LG Life Sciences, Ltd’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with LG Life Sciences, Ltd.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of LG Life Sciences, Ltd and identify potential opportunities in those areas.

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
LG Life Sciences, Ltd Snapshot 7
LG Life Sciences, Ltd Overview 7
Key Information 7
Key Facts 7
LG Life Sciences, Ltd – Research and Development Overview 8
Key Therapeutic Areas 8
LG Life Sciences, Ltd – Pipeline Review 11
Pipeline Products by Stage of Development 11
LG Life Sciences, Ltd – Pipeline Products Glance 12
LG Life Sciences, Ltd – Late Stage Pipeline 12
Registration Filed Products/Combination Treatment Modalities 12
Phase III Products/Combination Treatment Modalities 13
LG Life Sciences, Ltd Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
LG Life Sciences, Ltd–Early Stage Pipeline Products 16
Pre-Clinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
LG Life Sciences, Ltd – Drug Profiles 18
Anti-Obesity Drug 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Cytopro 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
DtwP-HB-Hib (Recon) Vaccine 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
EPO (Espogen) 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
FAAH Inhibitor 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Gemigliptin 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Glucokinase Activator 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
HIB vaccine 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
HPV vaccine 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
LB03002 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
LB80380 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
LBVH0101 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
LC350189 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Lercanidipine + Valsartan 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
P2Y12 Inhibitor 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
PAR-1 Inhibitor 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
TNFmab 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
XO Inhibitor 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
LG Life Sciences, Ltd – Pipeline Analysis 38
LG Life Sciences, Ltd – Pipeline Products by Therapeutic Class 38
LG Life Sciences, Ltd - Pipeline Products By Target 40
LG Life Sciences, Ltd – Pipeline Products by Route of Administration 42
LG Life Sciences, Ltd – Pipeline Products by Molecule Type 43
LG Life Sciences, Ltd – Recent Pipeline Updates 44
LG Life Sciences, Ltd - Dormant Projects 45
LG Life Sciences, Ltd – Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Recent Developments 47
Oct 29, 2009: LG Life Sciences Discovers Innovative Necrosis Inhibitors 47
Sep 27, 2011: Biopartners And LG Life Sciences Present Positive Phase III, 24 Months Efficacy And Safety Data For LB03002 Given To Children With Growth Hormone Deficiency 48
Apr 26, 2006: Completion of ANA380 Dosing in Phase II Clinical Trial Confirms Robust Activity Against Lamivudine-Resistant Hepatitis B Virus 48
Apr 18, 2005: Anadys Pharmaceuticals and LG Life Sciences Report Activity Against Lamivudine Resistant Strains in Phase II Clinical Trial of ANA380 for Hepatitis B 49
Apr 13, 2007: ANA380 Exhibits Activity In Vitro Against Multiple Clinically 50
Jun 11, 2009: Biopartners And LG Life Sciences Ltd Presents Positive Phase III Results 51
May 11, 2004: Anadys Pharmaceuticals & LG Life Sciences Announce Completion Phase I/IIa Clinical Trial ANA380 -LB80380- Patients Chronically Infected With Hepatitis B Virus 51
Jan 08, 2010: LG Life Sciences Receive KFDA Approval For Factive In Otitis Media 52
Financial Deals Landscape 53
LG Life Sciences, Ltd, Deals Summary 53
LG Life Sciences, Ltd, Pharmaceuticals & Healthcare, Deal Details 55
Partnerships 55
Green Cross Enters Into Co-Promotion Agreement With LG Life Sciences For Shinbaro 55
LG Life Sciences Enters Into Co-Development Agreement With Macrogen 56
LG Life Sciences Enters Into Co-Marketing Agreement With Anteis 57
LG Life Sciences Enters Into Co-Promotion Agreement With Sanofi-Aventis Korea 58
Shandong Luye Enters Into An Agreement With LG Life Sciences 59
ProStrakan Signs An Agreement With LG Life Sciences 60
LG Life Sciences Enters Into Co-Development Agreement With Institut Pasteur 61
LG Life Sciences Enters Into Co-Marketing Agreement With Novartis Korea 62
LG Life Sciences Enters Into Distribution Agreement With Sinovac Biotech 63
Sinovac Enters Into Co-Marketing Agreement With LG Life Sciences 64
LG Life Sciences Enters Into Co-Marketing Agreement With Novartis Korea 65
aRigen pharmaceuticals Enters Into Co-Marketing Agreement With LG Life Sciences 66
Licensing Agreements 67
Novavax Enters Into Licensing Agreement With LG Life Sciences 67
LG Life Sciences Enters Into Licensing Agreement With Nobel Ilac Sanayii ve Ticaret 68
LG Life Sciences Enters Into Licensing Agreement With Beijing Double-Crane 69
Gilead Sciences Enters Into Licensing Agreement With LG Life Sciences 70
Takeda Pharmaceutical Enters Into Licensing Agreement With LG Life Sciences 72
Depomed Amends Licensing Agreement With LG Life Sciences 73
Oscient Pharmaceuticals Amends Licensing Agreement With LG Life Sciences 74
Debiopharm Enters Into Licensing Agreement With LG Life Sciences 75
Kyorin Pharmaceutical Enters Into Licensing Agreement With LG Life Sciences 76
Veropharm Enters Into Licensing Agreement With LG Life Sciences For Factive 78
LG Life Sciences Enters Into Licensing Agreement With Depomed 79
Anadys Pharmaceuticals Enters Into Co-Development And Licensing Agreement With LG Life Sciences 80
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 83
Contact Us 83
Disclaimer 83

List of Tables
LG Life Sciences, Ltd – Pipeline by Therapy Area and Indication, H2 2011 10
LG Life Sciences, Ltd – Pipeline by Stage of Development, H2 2011 11
LG Life Sciences, Ltd – Filed, H2 2011 12
LG Life Sciences, Ltd – Phase III, H2 2011 13
LG Life Sciences, Ltd - Phase II, H2 2011 14
LG Life Sciences, Ltd - Phase I, H2 2011 15
LG Life Sciences, Ltd - Pipeline By Therapeutic Class, H2 2011 39
LG Life Sciences, Ltd - Pipeline By Target, H2 2011 41
LG Life Sciences, Ltd – Pipeline By Route of Administration, H2 2011 42
LG Life Sciences, Ltd – Pipeline By Molecule Type, H2 2011 43
LG Life Sciences, Ltd – Recent Pipeline Updates, H2 2011 44
LG Life Sciences, Ltd - Dormant Developmental Projects, 2010 45
LG Life Sciences, Ltd, Other Locations 46
LG Life Sciences, Ltd, Subsidiaries 46
LG Life Sciences, Ltd, Deals Summary 53
Green Cross Enters Into Co-Promotion Agreement With LG Life Sciences For Shinbaro 55
LG Life Sciences Enters Into Co-Development Agreement With Macrogen 56
LG Life Sciences Enters Into Co-Marketing Agreement With Anteis 57
LG Life Sciences Enters Into Co-Promotion Agreement With Sanofi-Aventis Korea 58
Shandong Luye Enters Into An Agreement With LG Life Sciences 59
ProStrakan Signs An Agreement With LG Life Sciences 60
LG Life Sciences Enters Into Co-Development Agreement With Institut Pasteur 61
LG Life Sciences Enters Into Co-Marketing Agreement With Novartis Korea 62
LG Life Sciences Enters Into Distribution Agreement With Sinovac Biotech 63
Sinovac Enters Into Co-Marketing Agreement With LG Life Sciences 64
LG Life Sciences Enters Into Co-Marketing Agreement With Novartis Korea 65
aRigen pharmaceuticals Enters Into Co-Marketing Agreement With LG Life Sciences 66
Novavax Enters Into Licensing Agreement With LG Life Sciences 67
LG Life Sciences Enters Into Licensing Agreement With Nobel Ilac Sanayii ve Ticaret 68
LG Life Sciences Enters Into Licensing Agreement With Beijing Double-Crane 69
Gilead Sciences Enters Into Licensing Agreement With LG Life Sciences 70
Takeda Pharmaceutical Enters Into Licensing Agreement With LG Life Sciences 72
Depomed Amends Licensing Agreement With LG Life Sciences 73
Oscient Pharmaceuticals Amends Licensing Agreement With LG Life Sciences 74
Debiopharm Enters Into Licensing Agreement With LG Life Sciences 75
Kyorin Pharmaceutical Enters Into Licensing Agreement With LG Life Sciences 76
Veropharm Enters Into Licensing Agreement With LG Life Sciences For Factive 78
LG Life Sciences Enters Into Licensing Agreement With Depomed 79
Anadys Pharmaceuticals Enters Into Co-Development And Licensing Agreement With LG Life Sciences 80

List of Figures
LG Life Sciences, Ltd – Pipeline by Therapy Area and Indication, H2 2011 9
LG Life Sciences, Ltd – Pipeline by Stage of Development, H2 2011 11
LG Life Sciences, Ltd – Pipeline By Therapeutic Class, H2 2011 38
LG Life Sciences, Ltd - Pipeline By Target, H2 2011 40
LG Life Sciences, Ltd – Pipeline By Route of Administration, H2 2011 42
LG Life Sciences, Ltd – Pipeline By Molecule Type, H2 2011 43

LG Life Sciences, Ltd – Product Pipeline Review – H2 2011

Published By: Global Markets Direct

Price:

How to Purchase

Purchase products from our site in 5 easy steps. Please follow the description given below to complete your purchase process.

Step 1:

Select the report title of your interest, and Click on Buy Now button next to the Price option.

Step 2:

You will arrive at the Purchase page, where you will be requested to Signup (New User) or Login (Registered User). Please note that in-keeping with the security check on the website, you must submit your full details to avoid any inconvenience arising from incorrectly entered data or counterfeit information.

Step 3:

After SignUp/Login, you will arrive at the Online Invoice Page. Select a Payment option via various methods: Debit Card / Credit Card / by Invoice. MarketReportOnline accepts Visa, MasterCard, American Express and all major credit cards. MarketReportOnline uses ICICI, HDFC, Citibank, American Express & Paypal as our Online Payment Gateway Partners. Clicking on a payment option will take you to the corresponding Payment Gateway page.

Step 4:

Once at the Payment Gateway, please complete the Payment Process to purchase your desired report.

Step 5:

Once you have successfully completed the purchase process, you will receive a confirmation email. You will then either be able to download your report immediately (in PDF Format) from the Account Login button, or the report will be emailed to you directly, depending upon the agreement we have with the publisher. For Orders that are deliverable via email and placed after working hours, the delivery of the reports will be made on the next business day. Please note, if you select purchase by invoice, you will receive your report only once the payment has been received. If you have any queries about how to order, please Contact Us .

sales@marketreportsonline.com + 1 888 391 5441

Using our subscription option, you get access to market research reports and industry data of Industry Profiles market as per your needs. Get the best of Industry Profiles research reports by utilizing your research budgets in an optimum way.
More about our Subscription option

Get Email alerts about market research reports from industries and publishers of your interest: